Nobuyoshi Fukumitsu1, Hitoshi Ishikawa2,3, Takeshi Arimura4, Hitoshi Wada5, Tomoaki Okimoto6, Yoshitaka Sato7, Hiromitsu Iwata8, Shosei Shimizu9, Hideyuki Sakurai9. 1. Department of Radiation Oncology, Kobe Proton Center, Hyogo, Japan. 2. Department of Radiation Oncology, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan ishikawa.hitoshi@qst.go.jp. 3. National Institutes for Quantum and Radiological Science and Technology, QST Hospital, Chiba, Japan. 4. Medipolis Proton Therapy and Research Center, Kagoshima, Japan. 5. Department of Radiation Oncology, Southern Tohoku Proton Therapy Center, Fukushima, Japan. 6. Department of Radiology, Hyogo Ion Beam Medical Center, Hyogo, Japan. 7. Proton Therapy Center, Fukui Prefectural Hospital, Fukui, Japan. 8. Departments of Radiation Oncology, Nagoya City West Medical Center, Aichi, Japan. 9. Department of Radiation Oncology, University of Tsukuba, Faculty of Medicine, Ibaraki, Japan.
Abstract
BACKGROUND/AIM: This multi-institutional study aimed to investigate the efficacy and feasibility of proton beam therapy (PBT) for renal cell carcinoma (RCC) in Japan. PATIENTS AND METHODS: The survival, local control, and toxicities in 22 RCC patients treated between 2001 and 2016 at 6 Japanese PBT institutes were analyzed. RESULTS: The 22 patients comprised 20 men and had a median age of 67 (range=42-88) years. The total irradiation dose was 60-79.6 Gy (relative biological effectiveness). Over a median follow-up of 37 months, the 3-year overall and disease-specific survival rates were 95% and 100%, respectively, and no recurrence occurred. No patient experienced grade 3 or higher adverse events. The serum blood urea nitrogen (p=0.25) and creatinine levels (p=0.95) were not significantly affected, although the mean estimated glomerular filtration rate was reduced by 7.1±11.2 ml/min/1.73 m2 Conclusion: Despite the small number of patients, high-dose PBT can control RCC while maintaining their renal function with high probability, and could be and alternative curative therapy especially for inoperable patients. Copyright
BACKGROUND/AIM: This multi-institutional study aimed to investigate the efficacy and feasibility of proton beam therapy (PBT) for renal cell carcinoma (RCC) in Japan. PATIENTS AND METHODS: The survival, local control, and toxicities in 22 RCCpatients treated between 2001 and 2016 at 6 Japanese PBT institutes were analyzed. RESULTS: The 22 patients comprised 20 men and had a median age of 67 (range=42-88) years. The total irradiation dose was 60-79.6 Gy (relative biological effectiveness). Over a median follow-up of 37 months, the 3-year overall and disease-specific survival rates were 95% and 100%, respectively, and no recurrence occurred. No patient experienced grade 3 or higher adverse events. The serum blood ureanitrogen (p=0.25) and creatinine levels (p=0.95) were not significantly affected, although the mean estimated glomerular filtration rate was reduced by 7.1±11.2 ml/min/1.73 m2 Conclusion: Despite the small number of patients, high-dose PBT can control RCC while maintaining their renal function with high probability, and could be and alternative curative therapy especially for inoperable patients. Copyright
Authors: Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2015-01-21 Impact factor: 20.096
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Rohann J M Correa; Alexander V Louie; Nicholas G Zaorsky; Eric J Lehrer; Rodney Ellis; Lee Ponsky; Irving Kaplan; Anand Mahadevan; William Chu; Anand Swaminath; Raquibul Hannan; Hiroshi Onishi; Bin S Teh; Alexander Muacevic; Simon S Lo; Michael Staehler; Shankar Siva Journal: Eur Urol Focus Date: 2019-06-24
Authors: Zev Leopold; Rachel Passarelli; Mark Mikhail; Alexandra Tabakin; Kevin Chua; Ronald D Ennis; John Nosher; Eric A Singer Journal: J Kidney Cancer VHL Date: 2022-08-15